Coordination of cell cycle and hematopoietic differentiation by a HoxA9/Myc/Cdk6 feedback loop
This study reveals that HoxA9 coordinates hematopoietic differentiation and cell cycle progression through a feedback loop where it sustains Cdk6/CyclinD1 activity to inhibit pRb-mediated repression, while Myc autonomously suppresses differentiation regulators Cebpa and Cdkn2d, collectively maintaining a block in differentiation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, a constant, quiet churn produces the blood that keeps us alive. This process, known as hematopoiesis, relies on a delicate balance between two opposing forces: the drive to multiply and the drive to mature. Stem cells must divide to replenish the supply, yet they must also stop dividing to transform into specialized cells like red blood cells or immune fighters. In healthy individuals, these two processes are tightly coordinated; a cell usually stops growing just as it begins to specialize. When this coordination fails, the result can be leukemia, a disease where blood cells multiply uncontrollably while remaining stuck in an immature, useless state. Scientists have long known that certain genes act as master switches for this process, but the precise molecular machinery that links the decision to divide with the decision to mature has remained a mystery.
A team of researchers at Friedrich-Alexander-University Erlangen-Nürnberg has now peeled back the layers of this mystery, focusing on a specific gene called HoxA9. In normal development, HoxA9 helps create blood precursors, but when it stays active for too long, it blocks cells from maturing, effectively trapping them in a state of endless division. The researchers wanted to understand how HoxA9 achieves this. They suspected that HoxA9 might be working in concert with two other well-known players in the cell cycle: a protein called Myc, which pushes cells to grow, and a molecular machine called Cdk6, which acts as a gas pedal for cell division. To test this, the team worked with primary blood cells from mice, using a sophisticated technique that allowed them to switch the HoxA9 gene off instantly, like flipping a light switch, and watch what happened next.
The experiment revealed a surprising hierarchy among these three players. When the researchers turned off HoxA9, the cells began to differentiate and stop dividing, as expected. However, when they added extra Myc to the mix, the cells refused to mature, even without HoxA9. The presence of Myc alone was enough to keep the cells in a state of arrested development. In contrast, adding extra Cdk6 and its partner protein CyclinD1 had no such effect; the cells differentiated normally. This suggested that while Cdk6 is part of the system, Myc is the primary force holding the cells back from maturing. The researchers then looked at the genetic instructions inside the cells to see how these proteins were talking to one another. They found that HoxA9 does not directly control Myc in a simple, immediate way. Instead, HoxA9 activates other genes that eventually lead to Myc production. More importantly, Myc acts as a suppressor, turning down the volume on two critical genes: one that drives differentiation and another that acts as a brake on Cdk6. By silencing these brakes, Myc keeps the cell cycle running and prevents the cell from ever deciding to grow up.
The story becomes even more intricate when looking at how Cdk6 fits into the picture. Although adding more Cdk6 did not stop differentiation on its own, the researchers found that Cdk6 is essential for HoxA9 to function at all. When they blocked Cdk6 activity using a drug called palbociclib, the cells immediately began to differentiate, even though HoxA9 was still present. This indicated that HoxA9 needs Cdk6 to do its job. Further investigation showed that HoxA9 physically binds to a protein called pRb, which is a known repressor of cell growth. Normally, Cdk6 phosphorylates pRb, releasing it so that cell division can proceed. The researchers discovered that HoxA9 latches onto pRb, preventing it from being released and effectively locking the cell in a state where it cannot divide or mature properly. This interaction creates a feedback loop: HoxA9 keeps the cell in a proliferative state by manipulating Myc and Cdk6, while Cdk6 activity is required to keep HoxA9 active.
To prove that this mechanism is central to the disease process, the researchers tested a different approach. They used a protein called Trib1, which is known to cooperate with HoxA9 in causing leukemia. Trib1 works by degrading the differentiation driver and stabilizing Myc, mimicking the effects of HoxA9 without actually needing the HoxA9 gene itself. When the researchers introduced Trib1 into blood cells, the cells transformed into a rapidly dividing, immature population. Crucially, when they removed Trib1, the cells stopped dividing and began to mature, just as they did when HoxA9 was removed. This confirmed that the core of the problem lies in the balance between Myc and the differentiation regulators, rather than HoxA9 itself being the sole culprit. The findings suggest that the cancerous state is maintained by a self-reinforcing circuit where Myc suppresses the cell's ability to mature, while Cdk6 activity ensures that HoxA9 remains active.
The implications of this work extend beyond understanding how the disease starts. The researchers showed that blocking Cdk6 with existing drugs could force these stubborn cancer cells to mature and stop dividing, offering a potential path for treatment. They also noted that the way these cells are controlled is highly sensitive to stress signals, such as those triggered by chemotherapy. If a cell is damaged, the body's natural stress response can activate p53, a protein that halts the cell cycle. This study suggests that this same stress response might also trigger differentiation by interfering with the HoxA9-Cdk6 loop, providing a biological explanation for why certain chemotherapy drugs work. The research does not claim to have solved leukemia, but it has mapped a specific, actionable circuit that keeps blood cells trapped in a state of arrested development. By understanding that the cell's decision to divide or mature is governed by this specific feedback loop involving Myc, Cdk6, and HoxA9, scientists can now look for ways to break the cycle and restore the natural order of blood production.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.